Form 4: Replimune Director Awarded 44,500 Stock Options

Director Madhavan Balachandran received 44,500 stock options with a $7.61 exercise price, scheduled to vest in April 2027.

Summary

• Madhavan Balachandran, a member of the Board of Directors, was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The grant is subject to a one-year cliff vesting schedule, with all shares vesting on April 1, 2027.
• The options have a ten-year term, expiring on April 1, 2036.
• The disclosure was filed with the SEC on April 7, 2026, which was noted as a late filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine compensation event; however, the score is tempered by the administrative error resulting in a late filing.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.
• Full vesting requires a one-year commitment, encouraging director retention.
• Exercise price of $7.61 provides a clear benchmark for future performance expectations.

Negatives

• The Form 4 was filed late, indicating a lapse in administrative regulatory compliance.
• Potential for future share dilution upon the exercise of these options.

Risks

• Administrative errors in SEC filings can occasionally signal internal control weaknesses in reporting.
• The value of the compensation is entirely dependent on the stock price exceeding $7.61 by the time of vesting and exercise.

Future Outlook

The reporting person will hold the right to acquire 44,500 shares of common stock starting in April 2027, assuming continued service on the board. This grant reinforces the long-term incentive structure for Replimune's leadership.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of director compensation in the biotechnology sector, designed to preserve cash while incentivizing board members to oversee clinical and commercial milestones that drive share price appreciation.

Comparison to Industry Standards

• The grant size of 44,500 options is consistent with mid-cap biotech board compensation packages.
• A one-year cliff vesting period is a common standard for annual director equity awards.
• The ten-year expiration term is the industry norm for incentive and non-qualified stock options.

Corporate Governance

Related Party Transactions

• Grant of stock options to a Director of the company as part of standard compensation.

Stakeholder Impact

• Shareholders may experience minor dilution if the options are exercised in the future.
• The grant signals continued board stability and alignment with company performance.

Next Steps

• Vesting of the options on April 1, 2027.

Key Dates

Recommendation

This is a routine insider transaction related to director compensation and does not typically signal a change in company fundamentals or immediate stock price movement.

Keywords

Replimune Group, REPL, Stock Options, Insider Trading, Director Compensation, Madhavan Balachandran, Equity Grant